Creation of arteriovenous fistula for hemodialysis in the older population

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00098892%3A_____%2F21%3AN0000023" target="_blank" >RIV/00098892:_____/21:N0000023 - isvavai.cz</a>

Výsledek na webu

<a href="https://biomed.papers.upol.cz/artkey/bio-202102-0011_creation-of-arteriovenous-fistula-for-hemodialysis-in-the-older-population.php" target="_blank" >https://biomed.papers.upol.cz/artkey/bio-202102-0011_creation-of-arteriovenous-fistula-for-hemodialysis-in-the-older-population.php</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.5507/bp.2020.013" target="_blank" >10.5507/bp.2020.013</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Creation of arteriovenous fistula for hemodialysis in the older population

Popis výsledku v původním jazyce

Objective. To evaluate the results of arteriovenous fistula (AVF) created for haemodialysis in patients older than 65 years of age. Subjects and Methods. A retrospective analysis of patients with AVF or arteriovenous graft (AVG) creation, who were older than 65 years of age and were operated on at the II. Surgical Clinic at the University Hospital in Olomouc from 2014 – 2018 was performed. Results. 212 patients were evaluated and a total of 239 AVF/AVG were created. 194 AVFs (81.18%) and 45 AVGs (18.82%) were created. Primary failure was seen in 19 arteriovenous fistulas (9.8%) and 2 arteriovenous grafts (4.44%). The primary patency of AVF was 69.9%, 62.8% after 12 and 24 months, respectively, and in the case of AVG it was 54.7% and 32.3% after 12 and 24 months, respectively. Primarily assisted patency of AVF was 77.6% and 66.3% after 12 and 24 months, respectively, and in case of AVG it was 69.1% and 39.7% after 12 and 24 months, respectively. Secondary patency of AVF was 77.6% and 66.3% after 12 and 24 months, respectively, and for AVG it was 69.1% and 39.7% after 12 and 24 months, respectively. Conclusion. The type of vascular access should be selected based on a thorough, protocol-based examination. In most seniors, AVF is the method of choice. The AVG is a suitable choice for patients with an exhausted venous bed, in acute need of haemodialysis, in the elderly and in females. A “customized” approach should be matter of fact for older generations.

Název v anglickém jazyce

Creation of arteriovenous fistula for hemodialysis in the older population

Popis výsledku anglicky

Objective. To evaluate the results of arteriovenous fistula (AVF) created for haemodialysis in patients older than 65 years of age. Subjects and Methods. A retrospective analysis of patients with AVF or arteriovenous graft (AVG) creation, who were older than 65 years of age and were operated on at the II. Surgical Clinic at the University Hospital in Olomouc from 2014 – 2018 was performed. Results. 212 patients were evaluated and a total of 239 AVF/AVG were created. 194 AVFs (81.18%) and 45 AVGs (18.82%) were created. Primary failure was seen in 19 arteriovenous fistulas (9.8%) and 2 arteriovenous grafts (4.44%). The primary patency of AVF was 69.9%, 62.8% after 12 and 24 months, respectively, and in the case of AVG it was 54.7% and 32.3% after 12 and 24 months, respectively. Primarily assisted patency of AVF was 77.6% and 66.3% after 12 and 24 months, respectively, and in case of AVG it was 69.1% and 39.7% after 12 and 24 months, respectively. Secondary patency of AVF was 77.6% and 66.3% after 12 and 24 months, respectively, and for AVG it was 69.1% and 39.7% after 12 and 24 months, respectively. Conclusion. The type of vascular access should be selected based on a thorough, protocol-based examination. In most seniors, AVF is the method of choice. The AVG is a suitable choice for patients with an exhausted venous bed, in acute need of haemodialysis, in the elderly and in females. A “customized” approach should be matter of fact for older generations.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30212 - Surgery

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2021

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Biomedical Papers-Olomouc  

ISSN

1213-8118

e-ISSN

1804-7521

Svazek periodika

165

Číslo periodika v rámci svazku

2

Stát vydavatele periodika

CZ - Česká republika

Počet stran výsledku

5

Strana od-do

179-183

Kód UT WoS článku

000660244900011

EID výsledku v databázi Scopus

2-s2.0-85108790774